Hematologic Malignancy
Cutaneous Mature T-Cell and NK-Cell Neoplasm
CI-CAN-00000794Explore in graph →
HematologicNon-malignant59 active trials10 approved drugs
- NCIt
- C45250
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000794Explore in graph →
Clinical trials
329 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01187446 | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 28 | Stanford UniversityOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant | terminated | Phase 2 | 3 | Fred Hutchinson Cancer CenterOTHER | 1 |
| Jul 27, 2017 |
| clinicaltrials |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | completed | Phase 2 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01110135 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | completed | Phase 2 | 43 | University of WashingtonOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00007345 | Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma | completed | Phase 2 | 131 | National Cancer Institute (NCI)NIH | 2 | May 16, 2017 | clinicaltrials |
| NCT00091559 | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) | completed | Phase 2 | 74 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 5, 2017 | clinicaltrials |
| NCT01396070 | Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | completed | Phase 2 | 36 | Youn KimOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT01637090 | Everolimus in Treating Cutaneous T-cell Lymphoma(CTCL) | terminated | Phase 2 | 3 | Adam LernerOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00226993 | Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. | withdrawn | Phase 1 / Phase 2 | 0 | Stanford UniversityOTHER | 0 | Dec 1, 2016 | clinicaltrials |
| NCT00611208 | A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 2 | 32 | Virogen Biotechnology Inc.INDUSTRY | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02213861 | Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma | unknown | Phase 2 | 60 | TetraLogic PharmaceuticalsINDUSTRY | 1 | Oct 20, 2016 | clinicaltrials |
| NCT02881749 | Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides | unknown | Phase 2 | 68 | Thomas Jefferson UniversityOTHER | 0 | Aug 30, 2016 | clinicaltrials |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT00178841 | Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL | completed | Phase 2 | 4 | Vanderbilt UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00131937 | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2015 | clinicaltrials |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas(PXD101-CLN-6) | terminated | Phase 2 | 53 | Valerio TherapeuticsINDUSTRY | 5 | Jul 28, 2015 | clinicaltrials |
| NCT00431912 | A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma | completed | Phase 2 | 25 | Valerio TherapeuticsINDUSTRY | 4 | Jul 8, 2015 | clinicaltrials |
| NCT01843998 | Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) | withdrawn | Phase 2 | 0 | Stefan Schieke MDOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | terminated | Phase 1 / Phase 2 | 28 | University of MichiganOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT00003210 | Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease | completed | Phase 2 | 105 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00099593 | Immunization Against Tumor Cells in Sezary Syndrome | completed | Phase 2 | 17 | University of PittsburghOTHER | 1 | Mar 25, 2015 | clinicaltrials |
| NCT01198665 | RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas(RADCHOP) | completed | Phase 1 / Phase 2 | 46 | Samsung Medical CenterOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT00185965 | CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas | completed | Phase 1 / Phase 2 | 30 | Ronald LevyOTHER | 1 | Aug 1, 2014 | clinicaltrials |
| NCT00863395 | Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma(CTCL) | terminated | Phase 1 / Phase 2 | 6 | University of MinnesotaOTHER | 1 | Mar 31, 2014 | clinicaltrials |
| NCT00005982 | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005080 | 506U78 in Treating Patients With Lymphoma | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00052377 | Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00699296 | Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma | terminated | Phase 2 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 27, 2012 | clinicaltrials |
| NCT00168064 | Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides | completed | Phase 2 | 260 | Yaupon TherapeuticsINDUSTRY | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00969085 | Trial of Curcumin in Cutaneous T-cell Lymphoma Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 7, 2012 | clinicaltrials |
| NCT00535470 | An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides | completed | Phase 2 | 100 | Yaupon TherapeuticsINDUSTRY | 1 | Aug 9, 2012 | clinicaltrials |
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 | clinicaltrials |
| NCT01132989 | Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma(REvMM2009) | unknown | Phase 2 | 10 | Florida Academic Dermatology CentersOTHER | 1 | May 28, 2010 | clinicaltrials |
| NCT00779896 | Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study | unknown | Phase 1 / Phase 2 | 15 | McGill UniversityOTHER | 1 | Oct 24, 2008 | clinicaltrials |
| NCT00157274 | Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome | unknown | Phase 2 | 20 | Latin American Cooperative Onco-Haematology Group - PeruOTHER | 1 | Apr 3, 2007 | clinicaltrials |
| NCT00306969 | Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | 18 | Boston UniversityOTHER | 1 | Mar 27, 2006 | clinicaltrials |
Data updated 23 days agoSource updated Nov 20, 2017source: clinicaltrials